The CheckMate816 trial examined neoadjuvant nivolumab in patients with resectable stage IB–IIIA NSCLC without EGFR or ALK mutations and found that neoadjuvant nivolumab with chemotherapy resulted in improved pathologic complete response and event-free survival compared to chemotherapy alone [32]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.